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Abstract
Background: The nature of the relationship between Helicobacter pylori and reflux oesophagitis is
still not clear. To investigate the correlation between Helicobacter pylori infection and GERD
taking into account endoscopic, pH-metric and histopathological data.
Methods: Between January 2001 and January 2003 a prospective study was performed in 146
patients with GERD in order to determine the prevalence of Helicobacter pylori infection at gastric
mucosa; further the value of the De Meester score endoscopic, manometric and pH-metric
parameters, i.e. reflux episodes, pathological reflux episodes and extent of oesophageal acid
exposure, of the patients with and without Helicobacter pylori infection were studied and statistically
compared. Finally, univariate analysis of the above mentioned data were performed in order to
evaluate the statistical correlation with reflux esophagitis.
Results: There were no statistically significant differences between the two groups, HP infected
and HP negative patients, regarding age, gender and type of symptoms. There was no statistical
difference between the two groups regarding severity of symptoms and manometric parameters.
The value of the De Meester score and the ph-metric parameters were similar in both groups. On
univariate analysis, we observed that hiatal hernia (p = 0,01), LES size (p = 0,05), oesophageal wave
length (p = 0,01) and pathological reflux number (p = 0,05) were significantly related to the
presence of reflux oesophagitis.
Conclusion: Based on these findings, it seems that there is no significant evidence for an important
role for H. pylori infection in the development of GERD and erosive esophagitis. Nevertheless,
current data do not provide sufficient evidence to define the relationship between HP and GERD.
Further assessments in prospective large studies are warranted.
Background
Helicobacter pylori (HP) has been demonstrated the caus-
ative factor of various gastrointestinal diseases; neverthe-
less, the relationship between HP infection and
gastroesophageal reflux disease (GERD) is still debated
[1]. To date, different studies have examined the relation-
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ship between atrophic gastritis due to HP infection and
reflux oesophagitis with conflicting results.
Recent trials suggest that HP infection may be an impor-
tant causative factor of atrophic gastritis [2]. HP infection
has been associated to inflammation of gastric mucosa
that increases cellular apoptosis and epithelium prolifera-
tion. The excessive apoptosis, leads to the atrophy of epi-
thelial cells and glands and could contribute to
carcinogenesis.
Some authors have found an increase of reflux oesophag-
itis after HP eradication. On the contrary, other authors
suggested a correlation between HP infection and pres-
ence and severity of reflux esophagitis [3].
It was suggested that HP could contribute to GERD
through different mechanisms: cardias inflammation
causing sphincter weakness; increased acid secretion due
to antral gastritis; delayed gastric emptying and citotoxin
production causing esophageal epithelium injury.
Conversely, other authors believe that HP infection may
even protect against GERD and HP eradication may lead
to an accelerated development of GERD in ulcer disease
patients [1,2,4-6]. Further, previous studies have shown
an increased effect of proton pump inhibitors on intragas-
tric pH in HP-infected patients suffering from GERD with
rapid heartburn relief and lack of relapse [7].
HP could play a protective role through different mecha-
nisms: decrease of acid secretion resulting from chronic
gastritis of the gastric body; improvement of gastro-
oesophageal junction due to proximal gastritis and finally
production of ammonium by the gastric colonization of
HP that could be a potential stopgap system [1-10].
The present prospective study was performed in 146
patients with GERD in order to determine the prevalence
of Helicobacter pylori (HP) infection at gastric mucosa;
furthermore the correlation between HP infection and
endoscopic, manometric, pH-metric and histological
findings was studied through the statistical comparison of
endoscopic, functional and histological data between
subjects with and without HP infection. Finally, we ana-
lysed the statistical correlation between reflux esophagitis
and HP infection, endoscopic, manometric, pH-metric
data.
Materials and methods
Between January 2001 and January 2003, 146 consecutive
patients with daily reflux symptoms for at least one year
were evaluated at the Department of Surgery, Tor Vergata
University Hospital, Rome and were included in this pro-
spective study.
The study had been approved by the Institutional Com-
mittee of the Tor Vergata University of Rome.
Exclusion criteria were the following: 1. Previous therapy
to eradicate HP. 2. Concomitant assumption of aspirin
and non-steroidal anti-inflammatory drugs 3. Previous
surgical procedures on digestive tract.
All patients underwent a pre-treatment evaluation, which
included anamnesis, clinical examination, EGDS with
biopsy, oesophageal manometry and 24 hours pH-metry.
Symptoms (heartburn, pain, and regurgitation) were
assessed by patients' visits.
Ambulatory manometry and pH studies were performed
using a conventional protocol. A catheter with three pres-
sure sensors (intersensor distance 5 cm) and one pH sen-
sor was used. The catheter was connected to an 8 Mb data-
logger with a sampling frequency of 4 Hz. After an over-
night fast the catheter was introduced transnasally and
placed in the esophagus. The lowermost pressure trans-
ducer was placed 2 cm above and the pH sensor placed 5
cm above the upper border of the lower esophageal
sphincter. The lower esophageal sphincter was identified
by the stepwise pull-through technique.
The pH and motility data were analyzed with the help of
a computer program (Multigram, V 6.30, Synectics Medi-
cal). The analyses of both pressure and pH data were done
separately for the total, upright (upright period excluding
the meal period), meal and supine periods according to
standard protocols.
Oesophageal manometry was performed in order to
define position, extension, pressure of LES (LES pressure:
normal range 14,3–34,5 mmHg), esophageal wave length
and height (table 1). Oesophageal motility and gastro-
esophageal junction coordination were evaluated using
damp deglutitions of 5 ml water bolus.
Twenty-four hours pH-metry was performed taking into
account the following parameters: 1. DeMeester score
value (normal value up to 14.7); 2. total number of reflux
episodes, number of pathological reflux episodes
(refluxes with pH<4 that least over 5 minutes); 3. extent of
oesophageal acid exposure; 4. type of reflux (in orto- and
clinostatism or total); 5. number of long acid reflux epi-
sodes 6. extent of the longest pathological reflux.
At endoscopy LES opening, presence of hiatus ernia, evi-
dent refluxes and esophagitis were evaluated. Esophagitis
was graded by endoscopy according to the Savary-Miller
classification: grade 0 indicates no lesions; grade 1, ery-
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exudative lesions; grade 2, multiple erosions affecting
multiple folds, not confluent; grade 3, multiple linear or
circumferential erosions that may be confluent; grade 4,
ulcer, stricture, or esophageal shortening, Barrett's epithe-
lium.
Barrett's esophagus has been defined as the presence of
squamo-columnar metaplasia localized at least 3 cm
above the oesophagus-gastric junction; 2–3 samples of
the lower oesophagus (last 3 cm) were obtained.
Endoscopic biopsy both of the gastric body and of the
antrum was performed in order to diagnose HP infection
and to obtain istological evaluation of the mucosa. HP
infection was diagnosed by either endoscopic evaluation
and color coded biopsy test.
Statistical analysis
All statistical elaborations were obtained by using Statig-
raphies 5 plus for Window XP (Statsoft; Tulsa, Okla, USA).
Results are expressed as mean values and standard devia-
tion (SD).
Quantitative variables between the two groups (HP posi-
tive and HP negative patients) were compared using the
Student's t-test; qualitative parameters were compared
between the two groups using chi-squared test.
Results were considered statistically significant at P < 0.05.
Results
The present study included 146 patients, 58 males and 88
females with a mean age of 51,5 ± 15,2 years (range 23–
89). All patients suffered from daily reflux symptoms for
at least one year. HP infection was diagnosed in 35
patients (24%), 13 males and in 22 females, while 111
patients (76%), 45 males and 66 females, were HP nega-
tive.
Patients with and without HP infection were statistically
compared. There were no significant differences between
the two groups regarding age, gender and presentation
symptoms.
Hiatal hernia was found in 97 cases out of 146 patients
(66.4%); 25 patients were HP positive (25.7%) and 72
were HP negative (74.3%).
Reflux esophagitis was evidenced by endoscopy in 41
patients (28%); according the Savary-Miller classification,
out of 146 patients, 105 were graded 0; 14 patients were
graded 1–3 (3 HP positive patients and 11 HP negative)
and finally 27 patients were graded 4 (9 HP positive
patients and 18 HP negative).
Impairment of oesophageal motility was detected at man-
ometry in 111 patients out of 146 (76%); HP was present
in 26 of these (23.5%) while 85 were HP negative
(76.5%).
Table 1: Definition of Esophageal Motility Disorders
Diagnoses Manometric impairments
Aperistalsis
Absent or simultaneous contractions (<30 mmHg)
Ineffective esophageal motility
≥3 peristaltic contractions with failure of wave progression or failed peristalsis over a segment of the distal 
esophagus
Normal
Normal velocity
Normal peristaltic amplitude
≥7 peristaltic contractions with an intact wave progression (amplitude >30 mmHg)
Nutcracker esophagus
Average peristaltic amplitude >180 mmHg over pressure sensors 3 and 8 cm above LES
Isolated hypertensive LES
Basal LES pressure greater than 45 mmHg
Distal esophageal spasm (DES)
Contractile velocity >8 cm/s mmHg over pressure sensors 3 and 8 cm above LES in ≥ 2 swallows
Atypical disorders of LES relaxation
Abnormal LES relaxation, may have simultaneous or absent peristalsis
Achalasia
Abnormal LES relaxation
Absent or simultaneous contractions
Modified from Pandolfino et al [48]World Journal of Surgical Oncology 2008, 6:74 http://www.wjso.com/content/6/1/74
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There was no statistical difference regarding LES pressure
between patients HP positive and HP negative (19,4 ±
95,0 (range 3,7–46.2) and 19,7 ± 115,0 (range 2,6–61)
respectively). Further, significant difference was evidenced
neither in oesophageal wave length (mean value 3.1 sec-
onds in HP-negative patients vs 3,2 seconds in HP posi-
tive) nor in oesophageal wave height (mean value 72,4 ±
39,3 in HP-negative patients vs 67,9 ± 28,4 in HP posi-
tive) (table 2).
The pH-metric parameters, i.e. reflux episodes, pathologi-
cal reflux episodes and extent of esophageal acid expo-
sure, were similar in both groups (table 3).
Out of 146 patients, 75 (51.4%) had pathological values
of De Meester score; 17 patients were HP positive (22.7%)
and 58 were HP negative (77.3%). Mean value of the De
Meester score was 35,9 ± 56,7 in HP positive patients vs.
33,3 ± 48 in HP negative and this difference was not sig-
nificant.
Further, there was no statistical difference regarding the
severity of symptoms complained by the patients between
the two groups (table 4).
In addition, to investigate the influence of the above men-
tioned clinical, endoscopic and functional variables on
reflux oesophagitis, a univariate analysis of clinical, endo-
scopic and functional parameters were performed consid-
ering the presence of oesophagitis as independent
variable.
We observed that hiatal hernia (p = 0,01), LES opening (p
= 0,05), oesophageal wave length (p = 0,01) and patho-
logical reflux number (p = 0,05) were significantly related
to the presence of oesophagitis. Differently HP infection
was not significantly related to the presence of reflux
oesophagitis.
Discussion
The incidence of HP infection in the patients with GERD,
varies widely in literature from 30% to 90% and is approx-
imately of 35% in most series [11].
It was suggested that HP could contribute to GERD
through different mechanisms: development of antral
gastritis that increases acid production, decrease of LES
pressure and impairment of gastric filling [12].
Nevertheless, the decreasing prevalence of HP infection
and related diseases (ulcer disease, gastric cancer) in west-
ern countries has been paralleled by an increased inci-
dence of gastro-esophageal reflux and related
complications. These epidemiological data do not sup-
port a causative role of HP for reflux disease, but suggest a
negative association [13].
Further, most trials on correlation between HP infection
and GERD have indicated no causal relationship [14,15].
Some other authors have even found a lower prevalence
of HP infection in patients with reflux symptoms and
have suggested a 'protective' role of HP infection against
the development of esophageal diseases [16,17]. These
authors believe that pre-existing LES dysfunction and gas-
tritis, susceptibility to reflux, increase of a latent reflux are
probably causative factors contributing to esophageal dis-
eases rather than HP infection [16].
Patients with HP-related corpus-predominant gastritis
may have reduced gastric acid probably mediated by
cytokines such as interleukin 1 [13].
Moreover, HP could improve the protective effect of LES
by neutralizing acid in the stomach through the activity of
urease [18,19]. Furthermore, some authors believe that
HP could increase the antisecretory effects of proton
pump inhibitors [20-22].
According to Javier and colleagues who found influence of
HP infection neither on pH-metric data nor on endo-
scopic findings [23], in our trial, out of 146 GERD
patients, only 24% were HP infected while 76% were HP
negative; in addition we found no statistical difference
regarding presence and severity of reflux esophagitis
between patients with and without HP infection. Besides,
Award and colleagues found that HP infection and hiatal
hernia in patients with esophageal reflux do not constitute
risk factors that affect the severity of esophagitis [24].
Table 2: Manometric data of 146 GERD patients
MANOMETRIC PARAMETERS HP positive HP negative P
Patients 35 111
LES pressure (mmHg) 19.4 ± 9.7 19.7 ± 10.7 NS
Motility impairment 26 (74.3%) 88 (79.3%) NS
Esophageal wave length (sec) 3.2 3.1 NS
Esophageal wave height 67.9 ± 28. 72.4 ± 39.3 NSWorld Journal of Surgical Oncology 2008, 6:74 http://www.wjso.com/content/6/1/74
Page 5 of 7
(page number not for citation purposes)
Most trials on correlation between HP infection and
GERD are based only on endoscopic observations. Actu-
ally, endoscopic pattern of GERD patients is often normal;
besides, the 24 hours pH-monitoring revealed high diag-
nostic accuracy for GERD [25,26].
Actually, even if it is undeniable the role of acid secretion
in esophageal lesions, it does not seem increased in GERD
patients [27-29]. In the present study we found no corre-
lation between HP infection and pH-metric data and the
mean value of DeMesteer point was similar in HP positive
and negative patients as found by Peters and colleagues
[30]. Further, the total time of acidification, was similar in
both groups as outlined by Oberg [31], who did not find
any correlations between HP infection and esophageal
exposure to acid, detected by 24 hours pH-metry, in
patients with erosive oesophagitis or Barrett's esophagus.
Schwizer studied 70 patients with GERD treated with lan-
soprazole associated to clarithromycin and amoxicillin in
patients with HP infection. There was no difference in 24-
h pH values before and after the HP eradication suggest-
ing that HP eradication did not affect distal oesophageal
acid exposure [32].
In addition, we found no significant correlation between
HP infection and hiatal hernia, considered by some
authors as a supporting element of GERD and signifi-
cantly associated with the development of oesophagitis
[33,34].
Virulent strains of HP, including those with a cytotoxin-
associated gene named cagA+, have been reported associ-
ated to significant gastric inflammation [13]. HP gastritis
is accompanied by release of nitric oxide, cytokines and
prostaglandins that may impair afferent nerve function,
reduce LES pressure and damage esophageal mucosa
[35,36]. Differently, according to other authors [36,37] in
our trial LES pressure was similar in patients with and
without HP infection, further, out of 146 GERD patients
only 26% had LES pressure < 14 mmHg, further, LES
opening (p = 0,05) and oesophageal wave length (p =
0,01) were significantly related to esophagitis.
Finally, the relationship between HP infection and gastric
adenocarcinoma is also controversy. Some authors sug-
gest an increased risk of gastric atrophy in patients HP
positive treated with long-term proton pump inhibitor
therapy. In a small subset of HP infected patients, chronic
gastritis may lead to gastric atrophy and intestinal meta-
plasia, potential precursor for gastric adenocarcinoma.
In a recent randomized controlled trial by Kuipers, none
of the HP-positive GERD patients treated with anti-reflux
surgery developed gastric atrophy, compared to 31% of
patients treated with proton pump inhibitor therapy for
an average of 5 years [38]. Differently, in a long-term trial
of GERD patients treated for years with omeprazole, there
was an increase both in severity of corpus gastritis and in
gastric atrophy in HP-positive patients [39]. Amongst the
HP infected patients, atrophy was detected in 12% at base-
line and 39% on follow-up.
On the contrary, it has been suggested that HP cagA+ may
potentially protect against complications of GERD, such
as Barrett's oesophagus and dysplasia/adenocarcinoma
[40,41]. The HP infection in patients with Barrett's
esophagus has reported in the 12%–60% of patents
[33,35,42-46]. A recent meta-analysis presented at Diges-
tive Disease Week 2002 reported a negative association
between the prevalence of both H. pylori and cagA+H.
pylori and reflux disease, Barrett's oesophagus and
oesophageal adenocarcinoma [47].
Conclusion
The exact association between HP and reflux disease con-
tinues to be debated. Our clinical, endoscopic manomet-
ric and pH-metric data shows significant role of HP
Table 3: pH-metric data of 146 GERD patients
pH-METRIC PARAMETERS HP positive HP negative P
Patients 35 111
Reflux episodes 113.9 ± 147.8 135.1 ± 129 NS
Pathological reflux episodes 3.3 ± 6.7 2.4 ± 4.3 NS
Esophageal acid exposure (min) 117 ± 195.2 109.3 ± 205.5 NS
De Meester score 35.9 ± 56.7 33.3 ± 48.4 NS
Table 4: Clinical parameters of 146 GERD patients
SYMPTOMS HP positive HP negative P
Patients 35/146 111/146
Regurgitation (%) 15 (42.8%) 68 (61.2%) N.S.
Dysphagia (%) 3 (8.6%) 23 (20.7%) N.S.
Heartburn (%) 16 (45.7%) 68 (61.2%) N.S.
Epigastric pain (%) 6 (17.%) 19 (17.1%) N.S.
Thoracic pain (%) 12 (34.3%) 50 (45%) N.S.
Dispepsia (%) 5 (14.3%) 19 (17.1%) N.S.
Other symptoms (%) 6 (17.1%) 23 (20.7%) N.S.World Journal of Surgical Oncology 2008, 6:74 http://www.wjso.com/content/6/1/74
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infection neither in the development of GERD nor in the
pathogenesis of reflux esophagitis. Nevertheless, current
data do not provide sufficient evidence to define the rela-
tionship between HP and GERD. However, this is an
evolving area with ongoing research and further assess-
ments in prospective large studies are warranted.
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